Novel Dual-Hormone Artificial Pancreas System Improves Glucose Control

HIGHLIGHTS

  • A Canadian study says that a novel dual-hormone artificial pancreas system can improve glucose control.
  • JDRF funded the study.

According to a Canadian study, a novel dual-hormone artificial pancreas system can improve glucose control in a better way, compared to a rapid insulin-alone artificial pancreas.

As part of an automated insulin delivery system, researchers from McGill University’s Faculty of Medicine combined pramlintide with insulin. Pramlintide is defined as a synthetic form of the hormone amylin. This hormone reduces post-meal blood glucose levels by inhibiting the action of the glucose-raising hormone glucagon. This study was funded by Juvenile Diabetes Research Foundation (JDRF).

Dr Ahmad Haidar, along with his research team (comprising of 57 researchers) proposed an approach in order to build on current findings from insulin-only artificial pancreas trials. Artificial pancreas using insulin can improve blood glucose control in people with type 1 diabetes. However, daytime control has remained suboptimal. Dr Haidar and his team also tested a regular system and a rapid system.

The conclusions of study are as follows:

“Compared with the rapid insulin-alone artificial pancreas system, the rapid insulin-and-pramlintide system increased the time in range from 74% to 84%, whereas the regular insulin-and-pramlintide system did not change the time in range.”

As pramlintide slowed down meal absorption and gave insulin more time to work, patients using the combination of hormones experienced significant improvement in the time spent within the target blood glucose range.

, , , , ,